Clinical Focus ›› 2022, Vol. 37 ›› Issue (9): 808-812.doi: 10.3969/j.issn.1004-583X.2022.09.008
Previous Articles Next Articles
Wang Zhenzhen1, Zhao shiyi2, Feng Siran1, Ma Boqing3()
Received:
2022-09-05
Online:
2022-09-20
Published:
2022-11-21
Contact:
Ma Boqing
E-mail:mboqing@126.com
CLC Number:
Wang Zhenzhen, Zhao shiyi, Feng Siran, Ma Boqing. Predictive value of neutrophil to lymphocyte ratio for microalbuminuria of patients with type 2 diabetes mellitus[J]. Clinical Focus, 2022, 37(9): 808-812.
Add to citation manager EndNote|Ris|BibTeX
URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2022.09.008
组别 | 例数 | 性别[例(%)] | 年龄 (岁) | BMI (kg/m2) | 糖尿病病程 (年) | 高血压病史[例(%)] | ||
---|---|---|---|---|---|---|---|---|
男 | 女 | 有 | 无 | |||||
正常组 | 236 | 134(56.8) | 102(43.2) | 57.36±12.14 | 25.39(23.46,27.73) | 10(3, 15) | 111(47.0) | 125(53.0) |
微量白蛋白尿组 | 164 | 93(56.7) | 71(43.3) | 60.87±13.95 | 25.64(23.39,28.34) | 9(4, 16) | 110(67.1) | 54(32.9) |
统计值 | χ2=0.000 | t=-2.613 | Z=-0.620 | Z=-1.228 | χ2=15.716 | |||
P值 | 0.989 | 0.009 | 0.535 | 0.219 | 0.000 |
组别 | 例数 | 性别[例(%)] | 年龄 (岁) | BMI (kg/m2) | 糖尿病病程 (年) | 高血压病史[例(%)] | ||
---|---|---|---|---|---|---|---|---|
男 | 女 | 有 | 无 | |||||
正常组 | 236 | 134(56.8) | 102(43.2) | 57.36±12.14 | 25.39(23.46,27.73) | 10(3, 15) | 111(47.0) | 125(53.0) |
微量白蛋白尿组 | 164 | 93(56.7) | 71(43.3) | 60.87±13.95 | 25.64(23.39,28.34) | 9(4, 16) | 110(67.1) | 54(32.9) |
统计值 | χ2=0.000 | t=-2.613 | Z=-0.620 | Z=-1.228 | χ2=15.716 | |||
P值 | 0.989 | 0.009 | 0.535 | 0.219 | 0.000 |
组别 | 例数 | WBC计数 (×109/L) | NEU计数 (×109/L) | LYM计数 (×109/L) | HbA1c (%) | FPG (mmol/L) | TC (mmol/L) | TG (mmol/L) | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
正常组 | 236 | 5.76 (5.07, 7.10) | 3.50 (2.92, 4.39) | 1.76 (1.42, 2.10) | 8.60 (6.93, 10.10) | 8.06 (6.19, 11.52) | 4.45 (3.67, 5.10) | 1.23 (0.93, 2.14) | |||||||
微量白蛋白尿组 | 164 | 6.67 (5.71, 7.77) | 4.17 (3.20, 5.06) | 1.76 (1.43, 2.22) | 8.50 (7.00, 10.60) | 7.70 (6.34, 11.85) | 4.33 (3.57, 5.29) | 1.57 (1.08, 2.38) | |||||||
Z值 | -4.297 | -3.921 | -0.663 | -1.000 | -0.158 | -0.321 | -2.516 | ||||||||
P值 | 0.000 | 0.000 | 0.507 | 0.318 | 0.875 | 0.749 | 0.012 | ||||||||
组别 | 例数 | HDL-C (mmol/L) | LDL-C (mmol/L) | BUN (mmol/L) | Scr (μmol/L) | eGFR [ml/(min·1.73 m2)] | UA (μmol/L) | NLR | |||||||
正常组 | 236 | 1.04 (0.85, 1.22) | 2.89 (2.33, 3.44) | 4.80 (4.20, 5.60) | 70.00 (62.93, 77.65) | 96.66 (83.19, 103.43) | 284.30 (237.70, 366.40) | 1.98 (1.65, 2.69) | |||||||
微量白蛋白尿组 | 164 | 0.96 (0.83, 1.12) | 2.81 (2.26, 3.53) | 5.40 (4.50, 6.70) | 74.80 (63.90, 85.10) | 86.54 (70.42, 99.65) | 292.00 (245.80, 354.90) | 2.30 (1.57, 3.53) | |||||||
Z值 | -2.445 | -0.516 | -4.297 | -3.424 | -4.404 | -0.191 | -2.089 | ||||||||
P值 | 0.014 | 0.606 | 0.000 | 0.001 | 0.000 | 0.848 | 0.037 |
组别 | 例数 | WBC计数 (×109/L) | NEU计数 (×109/L) | LYM计数 (×109/L) | HbA1c (%) | FPG (mmol/L) | TC (mmol/L) | TG (mmol/L) | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
正常组 | 236 | 5.76 (5.07, 7.10) | 3.50 (2.92, 4.39) | 1.76 (1.42, 2.10) | 8.60 (6.93, 10.10) | 8.06 (6.19, 11.52) | 4.45 (3.67, 5.10) | 1.23 (0.93, 2.14) | |||||||
微量白蛋白尿组 | 164 | 6.67 (5.71, 7.77) | 4.17 (3.20, 5.06) | 1.76 (1.43, 2.22) | 8.50 (7.00, 10.60) | 7.70 (6.34, 11.85) | 4.33 (3.57, 5.29) | 1.57 (1.08, 2.38) | |||||||
Z值 | -4.297 | -3.921 | -0.663 | -1.000 | -0.158 | -0.321 | -2.516 | ||||||||
P值 | 0.000 | 0.000 | 0.507 | 0.318 | 0.875 | 0.749 | 0.012 | ||||||||
组别 | 例数 | HDL-C (mmol/L) | LDL-C (mmol/L) | BUN (mmol/L) | Scr (μmol/L) | eGFR [ml/(min·1.73 m2)] | UA (μmol/L) | NLR | |||||||
正常组 | 236 | 1.04 (0.85, 1.22) | 2.89 (2.33, 3.44) | 4.80 (4.20, 5.60) | 70.00 (62.93, 77.65) | 96.66 (83.19, 103.43) | 284.30 (237.70, 366.40) | 1.98 (1.65, 2.69) | |||||||
微量白蛋白尿组 | 164 | 0.96 (0.83, 1.12) | 2.81 (2.26, 3.53) | 5.40 (4.50, 6.70) | 74.80 (63.90, 85.10) | 86.54 (70.42, 99.65) | 292.00 (245.80, 354.90) | 2.30 (1.57, 3.53) | |||||||
Z值 | -2.445 | -0.516 | -4.297 | -3.424 | -4.404 | -0.191 | -2.089 | ||||||||
P值 | 0.014 | 0.606 | 0.000 | 0.001 | 0.000 | 0.848 | 0.037 |
变量 | 回归 系数 | 标准误 | Wald χ2值 | P值 | OR值 | 95%CI | |
---|---|---|---|---|---|---|---|
下限 | 上限 | ||||||
高血压 | 0.732 | 0.234 | 9.755 | 0.002 | 2.078 | 1.304 | 3.289 |
BUN | 0.321 | 0.089 | 13.020 | 0.000 | 1.379 | 1.158 | 1.641 |
eGFR | -0.032 | 0.013 | 5.905 | 0.015 | 0.969 | 0.944 | 0.994 |
TG | 0.116 | 0.053 | 4.761 | 0.029 | 1.123 | 1.012 | 1.247 |
NLR | 0.206 | 0.094 | 4.788 | 0.029 | 1.228 | 1.022 | 1.477 |
常量 | 3.426 | 2.547 | 1.810 | 0.179 | 30.742 |
变量 | 回归 系数 | 标准误 | Wald χ2值 | P值 | OR值 | 95%CI | |
---|---|---|---|---|---|---|---|
下限 | 上限 | ||||||
高血压 | 0.732 | 0.234 | 9.755 | 0.002 | 2.078 | 1.304 | 3.289 |
BUN | 0.321 | 0.089 | 13.020 | 0.000 | 1.379 | 1.158 | 1.641 |
eGFR | -0.032 | 0.013 | 5.905 | 0.015 | 0.969 | 0.944 | 0.994 |
TG | 0.116 | 0.053 | 4.761 | 0.029 | 1.123 | 1.012 | 1.247 |
NLR | 0.206 | 0.094 | 4.788 | 0.029 | 1.228 | 1.022 | 1.477 |
常量 | 3.426 | 2.547 | 1.810 | 0.179 | 30.742 |
[1] |
Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition[J]. Diabetes Res Clin Pract, 2019, 157:107843.
doi: 10.1016/j.diabres.2019.107843 URL |
[2] |
Karakaya S, Altay M, Kaplan Efe F, et al. The neutrophil-lymphocyte ratio and its relationship with insulin resistance in obesity[J]. Turk J Med Sci, 2019, 49(1): 245-248.
doi: 10.3906/sag-1804-68 pmid: 30761879 |
[3] |
Zhang L, Long J, Jiang W, et al. Trends in chronic kidney disease in China[J]. N Engl J Med, 2016, 375(9): 905-906.
doi: 10.1056/NEJMc1602469 URL |
[4] |
Jaaban M, Zetoune AB, Hesenow S, et al. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as novel risk markers for diabetic nephropathy in patients with type 2 diabetes[J]. Heliyon, 2021, 7(7):e07564.
doi: 10.1016/j.heliyon.2021.e07564 URL |
[5] |
Tesch GH. Diabetic nephropathy-is this an immune disorder?[J]. Clin Sci (Lond), 2017, 131(16): 2183-2199.
doi: 10.1042/CS20160636 pmid: 28760771 |
[6] | Wan H, Wang Y, Fang S, et al. Associations between the neutrophil-to-lymphocyte ratio and diabetic complications in adults with diabetes: A cross-sectional study[J]. J Diabetes Res, 2020, 2020:6219545. |
[7] |
Uwaezuoke SN. The role of novel biomarkers in predicting diabetic nephropathy: A review[J]. Int J Nephrol Renovasc Dis, 2017, 10:221-231.
doi: 10.2147/IJNRD.S143186 pmid: 28860837 |
[8] |
Chen X, Ma J, Kwan T, et al. Blockade of HMGB1 attenuates diabetic nephropathy in mice[J]. Sci Rep, 2018, 8(1):8319.
doi: 10.1038/s41598-018-26637-5 pmid: 29844451 |
[9] |
Winter L, Wong LA, Jerums G, et al. Use of readily accessible inflammatory markers to predict diabetic kidney disease[J]. Front Endocrinol (Lausanne), 2018, 9:225.
doi: 10.3389/fendo.2018.00225 URL |
[10] | StojkovicLalosevic M, Pavlovic Markovic A, Stankovic S, et al. Combined diagnostic efficacy of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and mean platelet volume (MPV) as biomarkers of systemic inflammation in the diagnosis of colorectal cancer[J]. Dis Markers, 2019, 2019:6036979. |
[11] | Li H, Lu X, Xiong R, et al. High Neutrophil-to-lymphocyte ratio predicts cardiovascular mortality in chronic hemodialysis patients[J]. Mediators Inflamm, 2017, 2017:9327136. |
[12] |
Zhang Y, Lu JJ, Du YP, et al. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer[J]. Medicine (Baltimore), 2018, 97(12):e0144.
doi: 10.1097/MD.0000000000010144 URL |
[13] |
Wang Y, Sun K, Shen J, et al. Novel prognostic nomograms based on inflammation-related markers for patients with hepatocellular carcinoma underwent hepatectomy[J]. Cancer Res Treat, 2019, 51(4):1464-1478.
doi: 10.4143/crt.2018.657 pmid: 30913869 |
[14] | 姚青林, 王景杰, 李欢, 等. 中性粒细胞/淋巴细胞比率、C反应蛋白/白蛋白比率、血小板/淋巴细胞比率与结直肠癌患者预后的关系[J]. 疑难病杂志, 2020, 19(6):595-598+616. |
[15] | Liu J, Liu X, Li Y, et al. The association of neutrophil to lymphocyte ratio, mean platelet volume, and platelet distribution width with diabetic retinopathy and nephropathy: A meta-analysis[J]. Biosci Rep, 2018, 38(3):BSR20180172. |
[16] |
Kahraman C, Kahraman NK, Aras B, et al. The relationship between neutrophil-to-lymphocyte ratio and albuminuria in type 2 diabetic patients: A pilot study[J]. Arch Med Sci, 2016, 12(3):571-575.
doi: 10.5114/aoms.2016.59931 pmid: 27279850 |
[17] |
Kutlugun AA, Ebinc FA, Ozturk MT, et al. Association of neutrophil-to-lymphocyte ratio and microalbuminuria in patients with normal eGFR[J]. Rom J Intern Med, 2018, 56(1):21-26.
doi: 10.1515/rjim-2017-0036 pmid: 28945608 |
[18] | Wang JR, Chen Z, Yang K, et al. Association between neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and diabetic retinopathy among diabetic patients without a related family history[J]. DiabetolMetab Syndr, 2020, 12:55. |
[19] |
Khandare SA, Chittawar S, Nahar N, et al. Study of neutrophil-lymphocyte ratio as novel marker for diabetic nephropathy in type 2 diabetes[J]. Indian J Endocrinol Metab, 2017, 21(3): 387-92.
doi: 10.4103/ijem.IJEM_476_16 pmid: 28553592 |
[20] |
Zhou Y, Yuan J, Qi C, et al. Calcium dobesilate may alleviate diabetes-induced endothelial dysfunction and inflammation[J]. Mol Med Rep, 2017, 16(6):8635-8642.
doi: 10.3892/mmr.2017.7740 URL |
[21] | Warren AM, Knudsen ST, Cooper ME. Diabetic nephropathy: An insight into molecular mechanisms and emerging therapies[J]. Expert OpinTher Targets, 2019, 23(7):579-591. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||